A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in healthy adult males.

Key facts

Study ID

NCT02306876

Run by

Pfizer

People needed

77

Starts

2015-01-19

Expected to finish

2016-06-14

Last updated by the study team

2017-08-17

Who can join

Age: 18 and older, up to 45. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Medically healthy
• Male
• Right-handed aged
• 18-45 years
• BMI 17.5 to 35kg/m2.

You may not qualify if…

• Females
• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of screening and at the time of dosing).

Where it is running

• Arcadia MRI & Imaging Center — Arcadia, California, United States
• California Clinical Trials Medical Group — Glendale, California, United States
• Glendale Adventist Medical Center — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.